The FDA announced that ligelizumab has received the Breakthrough Therapy designation for the treatment of chronic spontaneous urticaria for patients who have had an inadequate response to H1-antihistamines.

The FDA has approved a new topical therapy for the treatment of actinic keratosis on the face or scalp.

The FDA recently approved a new topical treatment that is the first therapy approved in 40 years to target a new mechanism of action for acne.

The FDA has recently approved a new once-daily topical treatment for adult patients with plaque psoriasis.

The FDA approved guselkumab, a selective IL-23 inhibitor, for the treatment of adult patients with active psoriatic arthritis.

The FDA has approved a new topical foam medication for the treatment of inflammatory lesions caused by rosacea in adults.

The FDA approved a new therapy to increase pain-free light exposure in adult patients with a history of phototoxic reactions caused by erythropoietic protoporphyria.

The FDA recently approved a new topical retinoid for the treatment of acne on both the face and the trunk.

The FDA approved the expanded indication of topical dapsone 7.5% gel for the treatment of acne vulgaris in patients aged 9 to 11 years.